Validated Postbiotic Screening Confirms Presence of Physiologically-Active Metabolites, Such as Short-Chain Fatty Acids, Amino Acids and Vitamins in Hylak® Forte
- 160 Downloads
Hylak® forte is a postbiotic that inhibits the growth of pathogenic bacteria by reducing intestinal pH. It is assumed the potential presence of short-chain fatty acids (SCFAs) in Hylak® forte may contribute to this effect. In this current study, we analysed the composition of Hylak® forte, using a validated gas chromatography assay test method, to ascertain whether SCFAs are present in this postbiotic treatment. Hylak® forte was screened for C1 to C10 SCFAs by a gas chromatographic assay. In this assay, SCFAs were analysed as for their volatile ethyl ester derivatives in a 3.0 mL Hylak® forte sample. An additional screening procedure was conducted for the presence of vitamins and simple sugars. The gas chromatographic method for determining SCFAs was validated according to the requirements of ICH guideline Q2 (R1). Formic and acetic acids were identified in Hylak® forte at 27.92 ppm (90% confidence interval (CI), 26.90–28.94) and 306.17 ppm (90% CI, 277.11–335.22), respectively. Additional compounds were quantified in the solution, including vitamin B1 (0.029 mg/100 g), monosaccharides and disaccharides (2.767 g/100 g), as well as glutamic acid and glutamine (0.047 g/100 g). This study has identified formic acid in a range of 39.33 (90% CI, 36.50–42.17)–48.33 (90% CI, 45.91–50.76) ppm and acetic acid dropping down to 312.33 (90% CI, 295.32–329.35) from initial 415.67 ppm (90% CI, 385.93–445.41) in commercial Hylak® forte samples under forced degradation conditions. In addition, a range of other compounds in Hylak® forte was identified, including riboflavin and glutamine. Further studies are necessary to establish whether these compounds translate into tangible therapeutic effects.
KeywordsHylak forte SCFA Postbiotics Metabiotics Vitamins Gastrointestinal tract
This study was sponsored by Ratiopharm GmbH, which is an affiliate of Teva Pharmaceutical Industries Ltd. Medical writing support was provided by Matthew Gunther, PhD, of Zoetic Science, an Ashfield company, part of UDG Healthcare plc, and was funded by Ratiopharm GmbH (Ulm, Germany).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 6.Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, Blanchard C, Junt T, Nicod LP, Harris NL, Marsland BJ (2014) Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 20:159–166. https://doi.org/10.1038/nm.3444 CrossRefGoogle Scholar
- 12.Hylak® forte User Information. https://www.google.de/search?q=hylak+user+forte+user+infomration&rlz=1C1EJFA_enDE781DE781&oq=hylak+user+forte+user+infomration&aqs=chrome..69i57j33.7326j1j4&sourceid=chrome&ie=UTF-8. Accessed 20 Aug 2002, last revision March 2016
- 15.(2005) ICH harmonised tripartite guideline. Validation of analytical procedures: text and methodology Q2(R1). https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed 2016
- 18.Belousova EF, Nikitine YV, Mishurovskaya NC, Zlatkina AR (2005) Possibilities of microbial metabolite preparations for intestinal microbiota restoration. Cons Medicum 7:9–13Google Scholar
- 20.Konig H, Manz W, Singer U (1991) Influence on intestinal bacteria. Basic principles of treatment using bacterial metabolic products. Der Kassenarzt 18:52–61Google Scholar
- 21.Krieger D, Vanek E, Manz W, Elsasser R (1991) Influence of bacterial metabolic products on the fecal flora of healthy volunteers and on added pathogenic bacteria. Nb Med 4:169–172Google Scholar
- 23.Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T, Taylor TD, Itoh K, Kikuchi J, Morita H, Hattori M, Ohno H (2011) Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469:543–547. https://doi.org/10.1038/nature09646 CrossRefPubMedGoogle Scholar
- 33.Elshaghabee FMF, Bockelmann W, Meske D, de Vrese M, Walte HG, Schrezenmeir J, Heller KJ (2016) Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions. Front Microbiol 7:47. https://doi.org/10.3389/fmicb.2016.00047 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Tedelind S, Westberg F, Kjerrulf M, Vidal A (2007) Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 13:2826–2832. https://doi.org/10.3748/wjg.v13.i20.2826 CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, Pike NB, Strum JC, Steplewski KM, Murdock PR, Holder JC, Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord SM, Wise A, Dowell SJ (2003) The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278:11312–11319. https://doi.org/10.1074/jbc.M211609200 CrossRefPubMedGoogle Scholar
- 38.Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, di Yu, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, Mackay CR (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461:1282–1286. https://doi.org/10.1038/nature08530 CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME (2014) Expert consensus document. The international scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506–514. https://doi.org/10.1038/nrgastro.2014.66 CrossRefGoogle Scholar